Mubritinib–HSA Recognition: Binding and Function
2026-09-08
The reference study combines multispectroscopic analysis, biochemical testing, and molecular docking to define how mubritinib binds human serum albumin (HSA). It identifies moderate-affinity, site I binding with static fluorescence quenching and shows that the interaction alters HSA structure and esterase-like function, providing a mechanistic basis for interpreting mubritinib distribution and pharmacological behavior.
O-propargyl-puromycin for Protein Synthesis Assays
2026-09-08
O-propargyl-puromycin converts a short translation pulse into a click-compatible signal for imaging, flow cytometry, and proteomics. This article shows how to apply OPP to B-cell models of mitochondrial dysfunction while separating global translation changes from viability, subset composition, and protein-specific effects.
EDC.HCl Technical Workflow Guide
2026-09-07
EDC.HCl is a water-soluble carbodiimide used to activate carboxyl groups for amide bond formation with primary amines in peptide, bioconjugation, nucleotide, esterification, and lactonization workflows. The available information supports in vitro laboratory use only; no in vivo or clinical data are available for this reagent.
BHPF Inhibits GPER Signaling in Neuroblastoma Cells
2026-09-05
The reference study identifies fluorene-9-bisphenol (BHPF) as a direct inhibitor of G protein-coupled estrogen receptor 1 (GPER/GPR30), rather than simply an estrogen-receptor-active contaminant. By integrating molecular dynamics, receptor mutagenesis, gene knockout, calcium signaling, cytotoxicity, and expression analyses, the authors connect BHPF binding to impaired GPER signaling and neuroblastoma-cell toxicity.
Dasatinib: Mechanistic Assay Design
2026-09-05
Dasatinib (BMS-354825) can do more than suppress kinase activity: it can help separate Src–FAK signaling from EMT, stemness, and metastatic phenotypes. This guide integrates model-specific evidence with the mechanistic insights of a 2024 thymic epithelial tumor study to improve assay interpretation.
Gramine Suppresses TNBC Through CUL3–MTDH Ferroptosis
2026-09-04
A 2026 study identifies Gramine as a selective suppressor of triple-negative breast cancer through a CUL3–MTDH regulatory axis that triggers ferroptosis. By combining chemical screening, target-engagement assays, mechanistic rescue experiments, and mouse models, the work connects direct CUL3 binding with altered MTDH stability and ferroptotic tumor-cell death.
Dinaciclib for CDK and Tissue Boundary Research
2026-09-04
Dinaciclib (SCH727965) combines high-potency inhibition of CDK1, CDK2, CDK5, and CDK9 with practical readouts for cell-cycle and apoptosis studies. This article shows how to use the compound to connect cancer research with quantitative tissue-boundary assays while controlling for cytotoxicity and multi-CDK confounding.
Escitalopram: From SERT Assay to Clinical Context
2026-09-03
Escitalopram research is strongest when molecular selectivity and clinical endpoint interpretation are considered together. This guide connects Lexapro pharmacology, assay design, and evidence from anxious-depression research without confusing target engagement with therapeutic efficacy.
JXY, TLR4, and M1 Polarization in CAC
2026-09-03
Liu et al. show that Jiedu Xiaozheng Yin suppresses colitis-associated colorectal cancer in mice while shifting macrophages toward an M1-like phenotype through TLR4-associated signaling. The study combines an orthotopic disease model with macrophage-focused molecular and functional assays, offering a mechanistic framework for linking immune polarization with tumor progression.
Anlotinib hydrochloride in Angiogenesis Assays
2026-09-02
Anlotinib hydrochloride enables mechanism-led angiogenesis experiments by simultaneously probing VEGFR2, PDGFRβ, FGFR1, and downstream ERK signaling. This practical guide covers endothelial migration, capillary tube formation, pathway validation, comparative controls, and troubleshooting for cancer research workflows.
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-09-02
This open-access FASEB Journal study develops a nonviral lipid nanoparticle system for repeated intravesical delivery of chemically modified p21 mRNA. The results connect localized protein replacement with cell-cycle suppression, DNA-damage signaling, apoptosis, and tumor control in orthotopic bladder cancer models, while also highlighting the delivery and translational constraints that remain before clinical evaluation.
Hyperthermia Sensitizes BRCA2-Proficient Ovarian Cancer
2026-09-01
Mei et al. show that hyperthermia can lower BRCA2 protein abundance and increase Niraparib sensitivity in ovarian carcinoma models that retain BRCA2. The study links thermal treatment to impaired RAD51 focus formation, stronger tumor suppression, and longer survival with combined hyperthermia–PARP inhibition, suggesting a way to investigate acquired homologous recombination deficiency.
SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis
2026-09-01
The reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced chronic kidney injury, linking its activity to renal fibrosis, epithelial–mesenchymal transition, inflammation, and Smad3/STAT3 signaling. By combining an in vivo injury model with tubular epithelial cell experiments and two SMYD2-directed inhibitors, the work provides a mechanistic basis for evaluating SMYD2 inhibition in renal fibrosis while leaving important questions about target specificity and clinical translation unresolved.
Iptacopan Monotherapy in PNH: Study Findings
2026-08-31
This phase 2 proof-of-concept study evaluated oral factor B inhibition with Iptacopan (LNP023) as single-agent therapy in patients with active paroxysmal nocturnal hemoglobinuria. Rapid reductions in lactate dehydrogenase, improved hemoglobin levels, and reduced transfusion needs support proximal alternative complement pathway control, while the small, open-label design limits conclusions about long-term comparative efficacy.
HyperFluor 488 Goat Anti-Rabbit IgG Guide
2026-08-30
HyperFluor 488 Goat Anti-Rabbit IgG is a fluorescent antibody conjugate for detecting rabbit primary antibodies in immunofluorescence, microscopy, immunohistochemistry, immunocytochemistry, and flow cytometry workflows. It should not be treated as a universal secondary or a default live-cell reagent because the formulation contains sodium azide and assay-specific dilution and compatibility require validation.
461 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page